Background
death, PK/PD
Edited by: Prakash Radhakrishnan, University of Nebraska Medical Center, United StatesReviewed by: Longchao Liu, Chinese Academy of Sciences (CAS), China; Kazuya Ishida, Gilead, United StatesQL1604 is a humanized immunoglobulin G4 monoclonal antibody against programmed cell death protein 1. This first-in-human, open-label phase I study aimed to investigate the safety and tolerability and to identify the recommended doses of QL1604 for future studies. Pharmacokinetics/pharmacodynamics (PK/PD) and preliminary antitumor activity were also assessed.